Table 3.
Stratified analysis of the cDDD for bisphosphonate and non-bisphosphonate users.
| Case 1: bisphosphonate users | ||||
|---|---|---|---|---|
| pSS | Bisphosphonate users cDDD < 224 | Bisphosphonate users cDDD ≥ 224 | ||
| ADJ. HR | 95% CI | ADJ. HR | 95% CI | |
| No (Ref.) | 1.000 | 1.000 | ||
| Yes | 2.407* | (1.412–7.790) | 2.143* | (1.046–4.393) |
| Case 2: Non-bisphosphonate users | ||||
|---|---|---|---|---|
| pSS | Non-bisphosphonate users cDDD < 224 | Non-bisphosphonate users cDDD ≥ 224 | ||
| ADJ. HR | 95% CI | ADJ. HR | 95% CI | |
| No (ref.) | 1.000 | 1.000 | ||
| Yes | 0.447 | (0.128–1.562) | 0.549 | (0.121–2.493) |
(1) *0.01 ≤ p < 0.05, **0.0001 ≤ p < 0.01, ***p < 0.0001. (2) ‡ADJ. HR was adjusted by sex, comorbidities, and age at the initiation of bisphosphonate use.
cDDD cumulative dose with defined daily dose, 95% CI 95% confidence interval, ADJ. HR adjusted hazard ratio, Ref reference.